



STERIS plc (STE)

Updated July 27th, 2026, by Yiannis Zourmpanos

Key Metrics

Current Price:	\$218	5 Year Annual Expected Total Return:	11.3%	Market Cap:	\$21.5 B
Fair Value Price:	\$279	5 Year Growth Estimate:	5.0%	Ex-Dividend Date:	09/04/26 ¹
% Fair Value:	78%	5 Year Valuation Multiple Estimate:	1.8%	Dividend Payment Date:	09/25/26 ²
Dividend Yield:	1.2%	5 Year Price Target	\$356	Years Of Dividend Growth:	15
Dividend Risk Score:	B	Sector:	Health Care	Rating:	Hold

Overview & Current Events

STERIS plc (STE) is a global leader in infection prevention and other procedural products and services. Founded as Innovative Medical Technologies in Ohio in 1985, the company was later renamed STERIS in 1987. STERIS operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The company has a strong history of acquisitions, including American Sterilizer Company in 1987 and Amsco International in 1996, which expanded its product line for healthcare and sterilization. STERIS has a market capitalization of \$21.5 billion and a solid history of paying dividends.

On May 11th, 2026, the company announced financial results for the fourth quarter of fiscal year 2026. STE reported Q4 non-GAAP EPS of \$2.83, missing market estimates by \$0.02 and revenue of \$1.59 billion up 7.4%.

STERIS plc reported a record fiscal 2026 as full-year revenue increased 9% to \$5.9 billion, with constant currency organic revenue growth of 7%. Fourth-quarter net income from continuing operations climbed to \$220.3 million from \$146.5 million a year earlier, while adjusted net income improved to \$278.3 million. For the full year, net income from continuing operations increased to \$782.3 million from \$610.1 million, and adjusted net income reached \$1.0 billion, up from \$913.2 million in fiscal 2025. President and CEO Dan Carestio described fiscal 2026 as another record year, citing the company's diversified customer base and higher procedure volumes as key growth drivers.

Healthcare revenue increased 7% to \$1.14 billion, supported by growth across services, consumables and capital equipment, while Applied Sterilization Technologies revenue rose 6% to \$289.2 million and Life Sciences revenue advanced 9% to \$162.9 million. Operating cash flow strengthened to \$1.34 billion, with free cash flow rising to \$982.9 million. Looking ahead, STERIS expects fiscal 2027 revenue to increase 7-8%, supported by 6-7% constant currency organic growth. The board also approved a new \$1 billion share repurchase program, replacing the previous authorization.

Growth on a Per-Share Basis

Year	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2032
EPS	\$1.28	\$3.39	\$3.55	\$4.76	\$4.63	\$2.48	\$1.07	\$3.81	\$6.21	\$7.93	\$11.15	\$14.22
DPS	\$1.09	\$1.21	\$1.33	\$1.45	\$1.57	\$1.69	\$1.84	\$2.03	\$2.23	\$2.46	\$2.52	\$4.06
Shares³	85.5	85.0	84.6	84.8	85.2	97.5	99.7	98.8	98.6	98.2	100.0	108.5

STERIS plc operates in a growing healthcare industry that will positively influence its revenues over the long term. In addition, it has a strong track record of growth through acquisitions that helped expand its product offerings and geographical reach. For example, the acquisition of Cantel Medical expanded its product portfolio in infection prevention.

The most significant development for STERIS plc in 2023 was the completion of several tuck-in acquisitions. These acquisitions expanded their product and service offerings in the AST and Healthcare segments. The total aggregate

¹ Estimated ex-dividend date

² Estimated dividend payment date

³ In millions.

Disclosure: This analyst has no position in the security discussed in this research report, and no plans to initiate one in the next 72 hours.



STERIS plc (STE)

Updated July 27th, 2026, by Yiannis Zourmpanos

consideration for these acquisitions was approximately \$49.8 million, including a potential contingent consideration of \$7.3 million. This development allowed STERIS to enhance its capabilities and further strengthen its position in the market.

STERIS plc has reported strong growth in the past 10 years with an EPS CAGR of 22.5%. For the EPS forecast for 2027, we are using the midpoint of the analysts' estimate at \$11.15. Thus, with a forecasted annual growth of 5.0% the projected EPS in 2032 is \$14.22. STE has consistently increased its DPS, but at a slower growth for the last two years. However, we expect the DPS to remain on a rising trajectory through 2032.

Valuation Analysis

Year	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	Now	2032
Avg. P/E	18.5	20.5	22.6	25.7	27.8	27.6	194.8	55.4	326.1	28.9	22.9	25.00
Avg. Yld.	1.3%	1.2%	1.0%	0.9%	0.8%	0.8%	0.9%	0.9%	0.1%	1.1%	1.0%	1.1%

STERIS plc trades at a forward P/E of 22.9, below its normalized long-term average P/E of around 28.0. STERIS trades below its historical valuation multiples, but we consider a P/E of 25.0 as a fair reflection of the stock's valuation, suggesting a target price of \$356 by 2032.

Safety, Quality, Competitive Advantage, & Recession Resiliency


Year	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2032
Payout	85%	36%	37%	30%	34%	68%	172%	53%	36%	31%	23%	29%

STERIS plc is a leading provider of infection prevention and other healthcare solutions. Its competitive advantage lies in its ability to offer a comprehensive range of products and services that enable healthcare facilities to improve patient outcomes while reducing costs. STERIS plc has also demonstrated resilience during recessions, supported by its steady EPS performance during the 2007 recession. The company has a manageable debt-to-equity ratio of around 30%, indicating a healthy balance sheet. This financial stability and competitive edge position STERIS plc for long-term success in the healthcare industry. STERIS's board approved a new \$1 billion share repurchase program, replacing its previous authorization and providing the company with additional flexibility to return capital to shareholders through future buybacks.

Final Thoughts & Recommendation

STERIS' stock has increased since our last report. We remain confident that the acquisition synergies will materialize and be reflected in the company's financials in the following years. Thus, our hold rating is premised upon the 11.3% annualized total returns for the medium-term, derived from the forecasted earnings-per-share growth of 5.0%, a 1.2% starting dividend yield, and a valuation tailwind.

Total Return Breakdown by Year



Disclosure: This analyst has no position in the security discussed in this research report, and no plans to initiate one in the next 72 hours.



STERIS plc (STE)

Updated July 27th, 2026, by Yiannis Zourmpanos

Income Statement Metrics

Year	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Revenue	2,239	2,613	2,620	2,782	3,031	3,108	4,585	4,958	5,139	5,460
Gross Profit	895	1,026	1,093	1,175	1,320	1,343	2,016	2,160	2,218	2,419
Gross Margin	40.0%	39.3%	41.7%	42.2%	43.6%	43.2%	44.0%	43.6%	43.2%	44.3%
SG&A Exp.	627	682	632	670	717	731	1,503	1,299	1,252	1,334
Operating Profit	212	285	400	442	538	545	426	759	862	987
Op. Margin	9.5%	10.9%	15.3%	15.9%	17.7%	17.6%	9.3%	15.3%	16.8%	18.1%
Net Profit	111	110	291	304	408	397	244	107	378	612
Net Margin	4.9%	4.2%	11.1%	10.9%	13.5%	12.8%	5.3%	2.2%	7.4%	11.2%
Free Cash Flow	128	251	292	350	376	450	397	395	613	776
Income Tax	60	74	63	64	91	121	72	52	150	185

Balance Sheet Metrics

Year	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Total Assets	5,346	4,924	5,200	5,073	5,441	6,574	11,424	10,820	11,060	10,150
Cash & Equivalents	249	283	202	221	320	221	348	209	207	172
Acc. Receivable	472	483	528	565	586	609	799	928	1,008	1,044
Inventories	193	198	206	208	264	315	575	695	675	581
Goodwill & Int.	3,280	2,956	3,161	2,928	2,922	3,924	7,733	6,835	6,190	5,950
Total Liabilities	2,308	2,114	1,983	1,887	2,023	2,683	4,879	4,735	4,748	3,531
Accounts Payable	140	133	136	153	149	157	226	280	252	281
Long-Term Debt	1,568	1,478	1,316	1,183	1,151	1,651	3,088	3,079	3,206	2,168
Total Equity	3,023	2,799	3,206	3,178	3,405	3,881	6,532	6,077	6,302	6,603
D/E Ratio	0.52	0.53	0.41	0.37	0.34	0.43	0.47	0.51	0.51	0.33

Profitability & Per Share Metrics

Year	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Assets	3.0%	2.1%	5.7%	5.9%	7.8%	6.6%	2.7%	1.0%	3.5%	5.8%
Return on Equity	5.4%	3.8%	9.7%	9.5%	12.4%	10.9%	4.7%	1.7%	6.1%	9.5%
ROIC	3.5%	2.5%	6.6%	6.8%	9.1%	7.9%	3.2%	1.1%	4.1%	6.6%
Shares Out.	85.0	84.8	84.5	84.9	85.4	100.1	100.0	100.3	99.4	99.1
Revenue/Share	31.45	30.35	30.57	32.55	35.39	36.18	46.63	49.46	51.72	55.11
FCF/Share	1.80	2.92	3.41	4.09	4.39	5.24	4.04	3.94	6.17	

Note: All figures in millions of U.S. Dollars unless per share or indicated otherwise.

Disclaimer

Nothing presented herein is, or is intended to constitute, specific investment advice. Nothing in this research report should be construed as a recommendation to follow any investment strategy or allocation. Any forward-looking statements or forecasts are based on assumptions and actual results are expected to vary from any such statements or forecasts. No reliance should be placed on any such statements or forecasts when making any investment decision. While Sure Dividend has used reasonable efforts to obtain information from reliable sources, we make no representations or warranties as to the accuracy, reliability or completeness of third-party information presented herein. No guarantee of investment performance is being provided and no inference to the contrary should be made. There is a risk of loss from an investment in marketable securities. Past performance is not a guarantee of future performance.